Research
Hormonal
The potential effect of sitagliptin on blood glucose was lost by month 6 after treatment discontinuation.
This suggests that continuous treatment may be necessary to maintain glycemic control.
StrongRefutesmedium confidence
At 6 mo, mean 2-h OGTT values were identical in both groups, and no differences were observed in the percentage of patients with a normal 2-h OGTT or in mean HgbA1C.
Why this rating
The claim is based on a randomized controlled trial.
Source
Prevention of Posttransplant Diabetes: A Complex Problem Without a Simple Solution
Justin Oveyssi et al. · Transplantation · 2022
DOI 10.1097/tp.0000000000004374
rct · n=61
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Early treatment with the DPP-4 inhibitor, sitagliptin, did not lead to better glycemic control than placebo and did not prevent posttransplant diabetes (PTD).Strong
- The study failed to observe a statistically significant difference in the primary efficacy measure of ≥20 mg/dl difference in the 2-h OGTT at 3 months.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →